Abstract 1307P
Background
Sotorasib is the first KRAS G12C inhibitor that significantly improved PFS vs docetaxel in CodeBreaK 200 phase 3 study, with a median PFS of 5.6 months (mos) (HR: 0,66) and an acceptable safety profile. In France, sotorasib has been authorized from 12/2020 to 06/2023 through several programs of early access. Here, we present clinical characteristics of pts with KRAS G12C aNSCLC at progression after at least one previous line of treatment newly included in the post-marketing authorization early access (post-MA EA) from 06/2022 to 06/2023.
Methods
From 06/2022 to 10/2023, data from 1,121 pts newly treated by sotorasib in post-MA EA were collected in 272 centers.
Results
Main characteristics of this population are presented below: Table: 1307P
| Variable | Results |
| Median age, years [Q1-Q3] n=1,121 | 66.0 [30.2-91.3] |
| Male, % n=1,121 | 57.2 |
| Smoking status Non / former / regular or occasional, % n=1,118 | 3.2 / 80.2 / 16.5 |
| Adenocarcinoma, % n=1,120 | 95.6 |
| ECOG PS, % n=1,121 01≥2 | 20.260.219.6 |
PD-L1, % n=1,117 ConclusionsBetween 06/2022 and 10/2023, more than 1,600 pts were treated by sotorasib through French post-MA EA, highlighting the unmet therapeutic need. Clinical characteristics are consistent with those of CodeBreaK 200 trial pts. Interestingly, in post-MA EA, more pts received sotorasib in 2L, reflecting conditional marketing authorization granted in Europe, mostly after CT+IO in 1L. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyAmgen. FundingAmgen. DisclosureJ. Cadranel: Financial Interests, Personal, Advisory Board, Participation to boards: AMGEN, Jansen, AZ, MSD, Takeda, Daichi; Financial Interests, Institutional, Other, prospective: AbbVie; Financial Interests, Institutional, Advisory Board, Participation to boards: Sanofi, Novartis; Financial Interests, Personal, Invited Speaker, Participation to boards: BI; Financial Interests, Personal, Advisory Board, Participation to Boards: Pfizer; Financial Interests, Institutional, Research Grant, Support to academic trial: Pfizer; Financial Interests, Institutional, Research Grant, Preclinical research: Sanofi; Financial Interests, Institutional, Research Grant, Translational research: AbbVie; Non-Financial Interests, Principal Investigator, Trials: BMS, Jansen, Sanofi, AMGEN, Novartis, Pfizer, Daichi, BI, Takeda, AbbVie, AZ. H. Curcio: Financial Interests, Personal, Speaker, Consultant, Advisor: Viatris. Y. Oulkhouir: Financial Interests, Personal, Invited Speaker: Amgen. S. Couraud: Financial Interests, Personal and Institutional, Member of Board of Directors: Adene; Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Amgen, Boehringer; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, BMS, Takeda; Financial Interests, Institutional, Funding: BD, Celgene, Chugai, Lilly; Financial Interests, Personal, Speaker, Consultant, Advisor: Health Event; Financial Interests, Personal and Institutional, Sponsor/Funding: Janssen, MSD, Novartis, Pfizer, Sanofi; Financial Interests, Personal, Sponsor/Funding: MaaT Pharma, Pierre Fabre, SNCF; Financial Interests, Institutional, Sponsor/Funding: Roche, Transdiag, Volition. J. Mazieres: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Pfizer, Jiangsu Hengruii, Blueprint, Daiichi Sankyo, Novartis, Amgen; Financial Interests, Personal and Institutional, Research Grant: Roche, AstraZeneca, Pierre Fabre, BMS, Illumina. A. Métivier: Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, MSD, BMS, Novartis, Pfizer. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Family member is an employee: AstraZeneca. M. Wislez: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, BMS, F. Hoffman La Roche, Janssen, MSD Oncology, Lilly, Merck Serono, Novartis, Pfizer, Takeda, Sanofi, Leopharma; Non-Financial Interests, Personal, Other: Transgene. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. X. Quantin: Financial Interests, Institutional, Invited Speaker: Sanofi; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Other, Educational support: AstraZeneca. C. Naltet: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, MSD, Pfizer, BMS, Sanofi, Janssen, Amgen, Takeda; Non-Financial Interests, Personal, Sponsor/Funding: Roche. B. Roch: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, AstraZeneca, Amgen, Roche, Chugai, Lilly, Takeda; Non-Financial Interests, Personal, Non remunerated activity: MSD; Non-Financial Interests, Non remunerated activity: Novartis. L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, PharmaMar; Financial Interests, Institutional, Coordinating PI: Sanofi; Financial Interests, Personal, Local PI: Roche. C. Clément: Financial Interests, Personal, Full or part-time Employment: Amgen. L. De Gunten: Financial Interests, Personal, Full or part-time Employment: Amgen. V. Gounant: Financial Interests, Personal, Advisory Role: Janssen, Sanofi, Takeda, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca Pharmaceuticals LP; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb Co. All other authors have declared no conflicts of interest. Resources from the same session1260P - Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal studyPresenter: Ludovic Doucet Session: Poster session 05 1261P - Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutationsPresenter: Jie Wang Session: Poster session 05 1262P - Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistancePresenter: Tijmen van der Wel Session: Poster session 05 1263P - Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)Presenter: Hiroshige Yoshioka Session: Poster session 05 1264P - Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical needPresenter: John Heymach Session: Poster session 05 1265P - A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumoursPresenter: xianghai Cai Session: Poster session 05 1266P - Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohortPresenter: Amanda Tufman Session: Poster session 05 1267P - Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational studyPresenter: Naoto Takase Session: Poster session 05 1268P - Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLCPresenter: Jieun Park Session: Poster session 05 1269P - Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II studyPresenter: Luis Paz-Ares Session: Poster session 05 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|